A Name Change Won’t Fix the Disaster That Is Asensus Surgical
Too many underlying faults remain to consider ASXC stock worth the risk
Mar 10, 2021, 8:22 am EDT
March 10, 2021
Asensus Surgical (NYSEAMERICAN:
ASXC) (until recently known as TransEnterix) is a small biotech company seeking to commercialize surgical devices. ASXC stock has gone on a rocky ride over the past few years.
Source: Dmytro Zinkevych / Shutterstock.com
However, the company’s stock is back on the upswing. Shares have been rallying, and the upward trend got further juice on the news of Food and Drug Administration (FDA) approval for the company’s Senhance surgical platform.